Universal Biosensors, Inc. (UBI.AX)
AUD 0.05
(-1.89%)
AUD 0.05
(-1.89%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.61 Million AUD | -47.08% |
| 2022 | 20.05 Million AUD | 18.7% |
| 2021 | 16.89 Million AUD | -8.21% |
| 2020 | 18.4 Million AUD | 6.6% |
| 2019 | 17.26 Million AUD | -10.56% |
| 2018 | 19.3 Million AUD | -42.36% |
| 2017 | 33.49 Million AUD | -8.83% |
| 2016 | 36.73 Million AUD | 15.9% |
| 2015 | 31.69 Million AUD | 14.05% |
| 2014 | 27.79 Million AUD | 11.45% |
| 2013 | 24.93 Million AUD | 157.21% |
| 2012 | 9.69 Million AUD | -4.9% |
| 2011 | 10.19 Million AUD | 54.01% |
| 2010 | 6.61 Million AUD | 38.78% |
| 2009 | 4.76 Million AUD | -20.29% |
| 2008 | 5.98 Million AUD | 58.18% |
| 2007 | 3.78 Million AUD | 33.42% |
| 2006 | 2.83 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 8.2 Million AUD | -5.23% |
| 2024 Q1 | 9.23 Million AUD | -13.01% |
| 2024 Q2 | 8.65 Million AUD | -6.2% |
| 2023 Q1 | 19.95 Million AUD | -0.49% |
| 2023 Q4 | 10.61 Million AUD | -5.23% |
| 2023 FY | 10.61 Million AUD | -47.08% |
| 2023 Q2 | 14.25 Million AUD | -28.58% |
| 2023 Q3 | 11.19 Million AUD | -21.42% |
| 2022 Q2 | 21.53 Million AUD | -0.25% |
| 2022 FY | 20.05 Million AUD | 18.7% |
| 2022 Q1 | 21.58 Million AUD | 27.78% |
| 2022 Q3 | 23.28 Million AUD | 8.16% |
| 2022 Q4 | 20.05 Million AUD | -13.89% |
| 2021 FY | 16.89 Million AUD | -8.21% |
| 2021 Q4 | 16.89 Million AUD | 7.16% |
| 2021 Q1 | 16.02 Million AUD | -12.95% |
| 2021 Q2 | 15.29 Million AUD | -4.51% |
| 2021 Q3 | 15.76 Million AUD | 3.06% |
| 2020 Q4 | 18.4 Million AUD | -9.57% |
| 2020 Q1 | 21.76 Million AUD | 26.04% |
| 2020 Q2 | 20.86 Million AUD | -4.13% |
| 2020 FY | 18.4 Million AUD | 6.6% |
| 2020 Q3 | 20.35 Million AUD | -2.44% |
| 2019 Q3 | 14.89 Million AUD | 3.49% |
| 2019 FY | 17.26 Million AUD | -10.56% |
| 2019 Q2 | 14.39 Million AUD | -0.39% |
| 2019 Q1 | 14.45 Million AUD | -25.13% |
| 2019 Q4 | 17.26 Million AUD | 15.9% |
| 2018 Q4 | 19.3 Million AUD | -45.41% |
| 2018 Q1 | 35.37 Million AUD | 5.63% |
| 2018 FY | 19.3 Million AUD | -42.36% |
| 2018 Q2 | 35.82 Million AUD | 1.27% |
| 2018 Q3 | 35.36 Million AUD | -1.29% |
| 2017 Q2 | 34.73 Million AUD | 0.13% |
| 2017 Q3 | 34.29 Million AUD | -1.29% |
| 2017 Q4 | 33.49 Million AUD | -2.33% |
| 2017 FY | 33.49 Million AUD | -8.83% |
| 2017 Q1 | 34.69 Million AUD | -5.56% |
| 2016 Q1 | 34.37 Million AUD | 8.44% |
| 2016 FY | 36.73 Million AUD | 15.9% |
| 2016 Q4 | 36.73 Million AUD | 11.05% |
| 2016 Q3 | 33.07 Million AUD | -3.27% |
| 2016 Q2 | 34.19 Million AUD | -0.5% |
| 2015 Q2 | 30 Million AUD | -1.53% |
| 2015 Q3 | 31.08 Million AUD | 3.58% |
| 2015 Q1 | 30.47 Million AUD | 9.64% |
| 2015 Q4 | 31.69 Million AUD | 1.98% |
| 2015 FY | 31.69 Million AUD | 14.05% |
| 2014 FY | 27.79 Million AUD | 11.45% |
| 2014 Q3 | 26.02 Million AUD | 2.86% |
| 2014 Q1 | 24.85 Million AUD | -0.31% |
| 2014 Q4 | 27.79 Million AUD | 6.78% |
| 2014 Q2 | 25.3 Million AUD | 1.78% |
| 2013 Q4 | 24.93 Million AUD | 164.36% |
| 2013 Q2 | 9.99 Million AUD | -11.57% |
| 2013 Q1 | 11.3 Million AUD | 16.62% |
| 2013 FY | 24.93 Million AUD | 157.21% |
| 2013 Q3 | 9.43 Million AUD | -5.65% |
| 2012 Q4 | 9.69 Million AUD | -5.91% |
| 2012 Q3 | 10.3 Million AUD | 3.11% |
| 2012 Q2 | 9.99 Million AUD | 0.0% |
| 2012 FY | 9.69 Million AUD | -4.9% |
| 2011 Q3 | 7.66 Million AUD | 64.33% |
| 2011 Q2 | 4.66 Million AUD | 0.0% |
| 2011 Q4 | 10.19 Million AUD | 33.05% |
| 2011 FY | 10.19 Million AUD | 54.01% |
| 2010 Q4 | 6.61 Million AUD | 50.61% |
| 2010 Q3 | 4.39 Million AUD | 8.47% |
| 2010 FY | 6.61 Million AUD | 38.78% |
| 2010 Q2 | 4.05 Million AUD | 0.0% |
| 2009 Q2 | 5.29 Million AUD | 0.0% |
| 2009 FY | 4.76 Million AUD | -20.29% |
| 2009 Q4 | 4.76 Million AUD | 0.0% |
| 2008 FY | 5.98 Million AUD | 58.18% |
| 2008 Q4 | 3.8 Million AUD | 0.0% |
| 2008 Q2 | 4.39 Million AUD | 0.0% |
| 2007 Q2 | 3.49 Million AUD | 0.0% |
| 2007 FY | 3.78 Million AUD | 33.42% |
| 2007 Q4 | 3.31 Million AUD | 0.0% |
| 2006 FY | 2.83 Million AUD | 0.0% |
| 2006 Q4 | 2.7 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| 4DMedical Limited | 49.08 Million AUD | 78.381% |
| Adherium Limited | 3.4 Million AUD | -211.515% |
| Aroa Biosurgery Limited | 14.77 Million AUD | 28.19% |
| Atomo Diagnostics Limited | 1.29 Million AUD | -719.886% |
| Anteris Technologies Ltd | 17.03 Million AUD | 37.717% |
| Control Bionics Limited | 2.75 Million AUD | -284.568% |
| CardieX Limited | 8.56 Million AUD | -23.945% |
| Compumedics Limited | 22.14 Million AUD | 52.083% |
| Cochlear Limited | 904.6 Million AUD | 98.827% |
| CleanSpace Holdings Limited | 6.94 Million AUD | -52.705% |
| Cyclopharm Limited | 13.65 Million AUD | 22.279% |
| EMVision Medical Devices Ltd | 5.45 Million AUD | -94.524% |
| Nova Eye Medical Limited | 8.55 Million AUD | -24.094% |
| HeraMED Limited | 1.5 Million AUD | -604.714% |
| Imricor Medical Systems, Inc. | 25 Million AUD | 57.557% |
| ImpediMed Limited | 6.24 Million AUD | -69.991% |
| InhaleRx Limited | 911.41 Thousand AUD | -1064.407% |
| LBT Innovations Limited | 5.5 Million AUD | -92.675% |
| Micro-X Limited | 12.63 Million AUD | 16.0% |
| Neurotech International Limited | 314.69 Thousand AUD | -3272.287% |
| OncoSil Medical Limited | 1.98 Million AUD | -435.448% |
| PolyNovo Limited | 37.04 Million AUD | 71.351% |
| Respiri Limited | 3.55 Million AUD | -198.611% |
| SomnoMed Limited | 24.78 Million AUD | 57.174% |
| Uscom Limited | 2.07 Million AUD | -411.8% |
| Visioneering Technologies, Inc. | 2.76 Million AUD | -283.553% |